IRADIMED (IRMD) Reports Q2 EPS of $0.13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall St gains on chip stocks recovery; earnings draw focus
- Oil prices rise to five-week high on US-Iran attacks, Houthi blockade threat
- Chip stocks extend global rebound following last week's rout
- Citi's Chew says U.S. stock positioning unwind may not be over
- Adobe, Salesforce and Intuit fall as Morgan Stanley begins cautious coverage
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- Intersnack to acquire Utz Brands at $14.25 per share in go-private deal
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
Roth Capital Starts IRadimed Corp (IRMD) at Buy
August 11, 2014 7:52 AM EDTRoth Capital initiated coverage on IRadimed Corp (NASDAQ: IRMD) with a Buy rating and a price target of $14.00.
For an analyst ratings summary and ratings history on IRadimed Corp click here. For more ratings news on IRadimed Corp click here.
Shares of IRadimed Corp closed at $11.03 yesterday.
... More